Servier Pharmaceuticals/LinkedIn
Aug 12, 2025, 15:37
Servier’s Therapy for IDH Mutant Glioma was Nominated for 2025 Prix Galien USA Award
Servier Pharmaceuticals shared a post on LinkedIn:
“We’re proud to share that Servier’s therapy for Grade-2 IDH mutant glioma has been nominated for the Prix Galien USA Award in the Best Product for Rare/Orphan Diseases category!
It’s a true privilege to be recognized by The Galien Foundation for our work in delivering innovative treatment options to the glioma community.
Read the full announcement here.”
More posts featuring Servier on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54